Gossamer Bio Under Investigation After 80.1% Stock Plunge Following Trial Failure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 01 2026
0mins
Should l Buy GOSS?
Source: Businesswire
- Legal Investigation Initiated: The Schall Law Firm has announced an investigation into Gossamer Bio, focusing on potential violations of securities laws, particularly regarding the issuance of false or misleading statements that could affect investor decisions.
- Clinical Trial Failure: On February 23, 2026, Gossamer disclosed that its product candidate seralutinib failed to meet its primary endpoint in the Phase 3 PROSERA trial, leading to a significant loss of market confidence.
- Stock Price Plunge: Following this announcement, Gossamer's shares plummeted by over 80.1% on the same day, severely impacting shareholder investment value and potentially triggering further legal actions.
- Investor Rights Protection: The Schall Law Firm encourages affected shareholders to reach out for discussions on protecting their rights, demonstrating the firm's commitment to supporting investor interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.374
Low
10.00
Averages
12.33
High
15.00
Current: 0.374
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Lawsuit Announced for Gossamer Bio Investors
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Gossamer Bio (NASDAQ: GOSS) securities between June 16, 2025, and February 20, 2026, aiming to seek compensation for affected investors, indicating potential threats to the company's financial health.
- Compensation Structure: Investors joining the lawsuit will incur no out-of-pocket fees through a contingency fee arrangement, which reduces financial burdens and encourages more affected parties to participate, potentially leading to greater legal and financial pressure on the company.
- Lawsuit Context: The lawsuit alleges that Gossamer Bio made false and misleading statements regarding its Phase 3 PROSERA study while concealing critical negative information from investors, and if the allegations are proven true, it could severely impact the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resources in handling such cases, which may enhance investor confidence in the lawsuit's outcome.
See More
Gossamer Bio Faces Securities Class Action Lawsuit Following Phase 3 Trial Failure
- Lawsuit Background: A securities class action lawsuit has been filed against Gossamer Bio, Inc. following its February 23, 2026 announcement that the Phase 3 PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025 to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and exacerbating investor concerns about the company's future prospects, which may lead to a long-term decline in investor confidence.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, suggesting significant deficiencies in the company's transparency that affected investor decision-making.
- Listing Risk: Gossamer revealed on April 9, 2026, that it has not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market since February 24, 2026, which could lead to delisting risks, further impacting its financing capabilities and market reputation.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Gossamer Bio, aiming to recover damages for investors who purchased securities between June 16, 2025, and February 20, 2026, highlighting potential violations of federal securities laws.
- False Statements Allegation: The complaint alleges that Gossamer Bio concealed significant adverse facts regarding the design of its PROSERA study while promoting positive results, leading to artificially inflated stock prices and causing investors to buy shares at inflated levels.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by June 1, 2026, indicating the firm's commitment to safeguarding investor rights and laying the groundwork for future legal actions.
- Legal Fee Structure: The law firm operates on a contingency fee basis, meaning they will only charge fees if they successfully recover losses, which reduces legal risks for investors and enhances the appeal of participating in the lawsuit.
See More
Class Action Lawsuits Filed Against Gossamer Bio and Others
- Gossamer Bio Lawsuit: A class action lawsuit against Gossamer Bio alleges that during the period from June 16, 2025, to February 20, 2026, the company made materially false statements, misleading investors about the failure of its clinical trial to meet primary endpoints, which could significantly impact stock prices.
- New Era Energy Issues: The class action against New Era Energy reveals that from November 6, 2024, to December 29, 2025, the company overstated its progress on its Texas data center project and was involved in fraudulent activities, potentially leading to substantial financial losses for investors.
- Medpace Holdings Risks: Medpace Holdings is accused of misrepresenting its projected book-to-bill ratio from April 22, 2025, to February 9, 2026, failing to disclose the impact of order cancellations on its financial health, which may mislead investors regarding the company's prospects.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses in the aforementioned companies to contact legal counsel promptly to understand their rights and ensure they participate in the class actions effectively.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and severely undermining investor confidence in the company's future, which may lead to further capital outflows.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, and if confirmed, this could lead to broader legal liabilities for the company.
- Investor Losses: The lawsuit encourages investors who suffered substantial losses during the class period to submit claims, highlighting a strong investor concern over the company's transparency and information disclosure, which could impact future investor trust and market performance.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: The stock price of Gossamer plummeted by 80% after the trial results failed to show statistical significance, which not only undermines investor confidence but also poses a risk to the company's continued listing on Nasdaq due to minimum bid price requirements.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer misled investors regarding trial design and patient recruitment protocols, and if confirmed, this could lead to more severe legal repercussions for the company.
- Investor Losses: The lawsuit encourages investors who suffered significant losses during the class period to submit claims, reflecting serious concerns about the company's future financial health and potentially impacting its ability to raise capital and maintain market reputation.
See More
Class Action Lawsuit Announced for Gossamer Bio Investors
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Gossamer Bio (NASDAQ: GOSS) securities between June 16, 2025, and February 20, 2026, aiming to seek compensation for affected investors, indicating potential threats to the company's financial health.
- Compensation Structure: Investors joining the lawsuit will incur no out-of-pocket fees through a contingency fee arrangement, which reduces financial burdens and encourages more affected parties to participate, potentially leading to greater legal and financial pressure on the company.
- Lawsuit Context: The lawsuit alleges that Gossamer Bio made false and misleading statements regarding its Phase 3 PROSERA study while concealing critical negative information from investors, and if the allegations are proven true, it could severely impact the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resources in handling such cases, which may enhance investor confidence in the lawsuit's outcome.
See More
Gossamer Bio Faces Securities Class Action Lawsuit Following Phase 3 Trial Failure
- Lawsuit Background: A securities class action lawsuit has been filed against Gossamer Bio, Inc. following its February 23, 2026 announcement that the Phase 3 PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025 to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and exacerbating investor concerns about the company's future prospects, which may lead to a long-term decline in investor confidence.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, suggesting significant deficiencies in the company's transparency that affected investor decision-making.
- Listing Risk: Gossamer revealed on April 9, 2026, that it has not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market since February 24, 2026, which could lead to delisting risks, further impacting its financing capabilities and market reputation.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Gossamer Bio, aiming to recover damages for investors who purchased securities between June 16, 2025, and February 20, 2026, highlighting potential violations of federal securities laws.
- False Statements Allegation: The complaint alleges that Gossamer Bio concealed significant adverse facts regarding the design of its PROSERA study while promoting positive results, leading to artificially inflated stock prices and causing investors to buy shares at inflated levels.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by June 1, 2026, indicating the firm's commitment to safeguarding investor rights and laying the groundwork for future legal actions.
- Legal Fee Structure: The law firm operates on a contingency fee basis, meaning they will only charge fees if they successfully recover losses, which reduces legal risks for investors and enhances the appeal of participating in the lawsuit.
See More
Class Action Lawsuits Filed Against Gossamer Bio and Others
- Gossamer Bio Lawsuit: A class action lawsuit against Gossamer Bio alleges that during the period from June 16, 2025, to February 20, 2026, the company made materially false statements, misleading investors about the failure of its clinical trial to meet primary endpoints, which could significantly impact stock prices.
- New Era Energy Issues: The class action against New Era Energy reveals that from November 6, 2024, to December 29, 2025, the company overstated its progress on its Texas data center project and was involved in fraudulent activities, potentially leading to substantial financial losses for investors.
- Medpace Holdings Risks: Medpace Holdings is accused of misrepresenting its projected book-to-bill ratio from April 22, 2025, to February 9, 2026, failing to disclose the impact of order cancellations on its financial health, which may mislead investors regarding the company's prospects.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses in the aforementioned companies to contact legal counsel promptly to understand their rights and ensure they participate in the class actions effectively.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and severely undermining investor confidence in the company's future, which may lead to further capital outflows.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, and if confirmed, this could lead to broader legal liabilities for the company.
- Investor Losses: The lawsuit encourages investors who suffered substantial losses during the class period to submit claims, highlighting a strong investor concern over the company's transparency and information disclosure, which could impact future investor trust and market performance.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: The stock price of Gossamer plummeted by 80% after the trial results failed to show statistical significance, which not only undermines investor confidence but also poses a risk to the company's continued listing on Nasdaq due to minimum bid price requirements.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer misled investors regarding trial design and patient recruitment protocols, and if confirmed, this could lead to more severe legal repercussions for the company.
- Investor Losses: The lawsuit encourages investors who suffered significant losses during the class period to submit claims, reflecting serious concerns about the company's future financial health and potentially impacting its ability to raise capital and maintain market reputation.
See More
